DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1

International Journal of Cancer

Volumn 133, Issue 6, 2013, Pages 1400-1407

  Campos Perez, Juan ^a   Rice, Jason ^a   Escors, David ^b,c   Collins, Mary ^b   Paterson, Alex ^a   Savelyeva, Natalia ^a   Stevenson, Freda K ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

cancer testis antigens; cytotoxic T cells; DNA vaccines; tumor peptides

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; CYSTEINE; DNA VACCINE; EPITOPE; HLA A2 ANTIGEN; NY ESO 1 ANTIGEN; PEPTIDE DERIVATIVE; PEPTIDE VACCINE; SERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHANYLISOLEUCYLTHREONYLGLUTAMINYLCYSTEINE; SERYLLEUCYLLEUCYLMETHIONYLTRYPTOPHANYLISOLEUCYLTHREONYLGLUTAMINYLLEUCINE; SYNTHETIC PEPTIDE; TETANUS TOXIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENE TARGETING; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; TUMOR CELL; VACCINE PRODUCTION;

CANCER TESTIS ANTIGENS; CYTOTOXIC T CELLS; DNA VACCINES; TUMOR PEPTIDES;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CYSTEINE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; VACCINES, DNA;

EID: 84879990654     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28156     Document Type: Article

References (39)

1. Caballero OL, Chen YT,. Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009; 100: 2014-21.
2. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30.
3. Gnjatic S, Nagata Y, Jager E, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci USA 2000; 97: 10917-22.
4. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70.
5. Shang XY, Chen HS, Zhang HG, et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 2004; 10: 6946-55.
6. Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2000; 60: 4499-506.
7. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000; 97: 12198-203.
8. Davis ID, Chen W, Jackson H, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101: 10697-702.
9. Bioley G, Guillaume P, Luescher I, et al. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J Immunother 2009; 32: 161-8.
10. Valmori D, Souleimanian NE, Tosello V, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007; 104: 8947-52.
11. Karbach J, Gnjatic S, Bender A, et al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010; 126: 909-18.
12. Odunsi K, Matsuzaki J, Karbach J, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci USA 2012; 109: 5797-802.
13. Chen W, Yewdell JW, Levine RL, et al. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J Exp Med 1999; 189: 1757-64.
14. Webb AI, Dunstone MA, Chen W, et al. Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J Biol Chem 2004; 279: 23438-46.
15. Chen JL, Dunbar PR, Gileadi U, et al. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J Immunol 2000; 165: 948-55.
16. Valmori D, Ayyoub M,. Using modified antigenic sequences to develop cancer vaccines: are we losing the focus? PLoS Med 2004; 1: e26.
17. Iero M, Filipazzi P, Castelli C, et al. Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? Cancer Immunol Immunother 2009; 58: 1159-67.
18. Rice J, Elliott T, Buchan S, et al. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J Immunol 2001; 167: 1558-65.
19. Rice J, Dossett ML, Ohlen C, et al. DNA fusion gene vaccination mobilizes effective anti-leukemic cytotoxic T lymphocytes from a tolerized repertoire. Eur J Immunol 2008; 38: 2118-30.
20. Chudley L, McCann K, Mander A, et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol Immunother 2012;61:2161-70.
21. Lethe B, Lucas S, Michaux L, et al. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998; 76: 903-8.
22. Rice J, Dunn S, Piper K, et al. DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res 2006; 66: 5436-42.
23. Chaise C, Buchan SL, Rice J, et al. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance. Blood 2008; 112: 2956-64.
24. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185: 2043-51.
25. Alexander J, Sidney J, Southwood S, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1: 751-61.
26. Rice J, Buchan S, Dewchand H, et al. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J Immunol 2004; 173: 4492-9.
27. Palmowski MJ, Lopes L, Ikeda Y, et al. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol 2004; 172: 1582-7.
28. Escors D, Lopes L, Lin R, et al. Targeting dendritic cell signaling to regulate the response to immunization. Blood 2008; 111: 3050-61.
29. Selden C, Mellor N, Rees M, et al. Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med 2007; 9: 67-76.
30. Rice J, King CA, Spellerberg MB, et al. Manipulation of pathogen-derived genes to influence antigen presentation via DNA vaccines. Vaccine 1999; 17: 3030-8.
31. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-18.
32. Gnjatic S, Jager E, Chen W, et al. CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci USA 2002; 99: 11813-18.
33. Theodossis A, Guillonneau C, Welland A, et al. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition. Proc Natl Acad Sci USA 2010; 107: 5534-5539.
34. Rice J, Ottensmeier CH, Stevenson FK,. DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008; 8: 108-20.
35. Gnjatic S, Altorki NK, Tang DN, et al. NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells. Clin Cancer Res 2009; 15: 2130-9.
36. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 2003; 421: 852-6.
37. Speiser DE, Baumgaertner P, Voelter V, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci USA 2008; 105: 3849-54.
38. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-78.
39. Mathiesen I,. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-14.